Sanofi Genzyme (Genzyme or ‘the company’), a wholly-owned subsidiary of Sanofi, is engaged in the field of biotechnology. The company's product and service portfolio is focused on rare diseases, multiple sclerosis, oncology and immunology. The company has sites in more than 40 locations around the world serving patients in more than 100 countries.

The company operates through two business units: rare diseases, multiple sclerosis, oncology and immunology.

Genzyme's rare disease business unit is focused on products for the treatment of rare genetic diseases and other chronic debilitating diseases, including lysosomal storage disorders (LSD), a group of metabolic disorders caused by enzyme deficiencies and endocrinology. Its products include: Cerezyme (imiglucerase for injection), an enzyme replacement therapy used to treat Gaucher disease, an inherited, potentially life-threatening LSD; Cerdelga (eliglustat), a first-line oral therapy for Gaucher disease Type 1; Myozyme / Lumizyme (alglucosidase alfa), enzyme replacement therapies used to treat Pompe disease, an inherited, progressive and often fatal LSD; Fabrazyme (agalsidase beta), an enzyme replacement therapy used to treat Fabry disease, an inherited, progressive and potentially life threatening LSD; and Aldurazyme (laronidase), an enzyme replacement therapy used to treat Mucopolysaccharidosis Type 1 (MPS I).

The multiple sclerosis business segment focuses on the development and commercialization of therapies to treat multiple sclerosis. The company’s products include: Aubagio (teriflunomide), an oral immunomodulator and Lemtrada (alemtuzumab), a humanized monoclonal antibody. Genzyme has multiple sclerosis research and development (R&D) pipeline focused on investigational treatments to address unmet needs for relapsing and progressive forms. Its R&D programs are pursuing research in selective immunomodulation, neuroprotection and remyelination.

The company’s oncology business unit is focused on products for the treatment of cancers such as prostate cancer. Key products include Jevtana (cabazitaxel), a cytotoxic agent for the treatment of patients with hormone-refractory metastatic prostate cancer; Taxotere (docetaxel), a taxoid class derivative that inhibits cancer cell division by essentially freezing the cell’s internal skeleton; Eloxatin (oxaliplatin), a platinum-based cytotoxic agent for adjuvant treatment of people with stage III colon cancer who have had their primary tumors surgically removed; Thymoglobulin (Anti-thymocyte Globulin), a polyclonal anti-human thymocyte antibody preparation that acts as a broad immuno-suppressive and immuno-modulating agent; Mozobil (plerixafor injection), a hematopoietic stem cell mobilizer for patients with non-Hodgkin’s lymphoma and multiple myeloma; and Zaltrap (aflibercept), a recombinant fusion protein that binds to vascular endothelial growth factor-A (VEGF-A), vascular endothelial growth factor-B (VEGF-B) and placental growth factor (PIGF), preventing the bound VEGF from binding to their native receptors. VEGF-A is one of the mediators contributing to angiogenesis. VEGF-B and PlGF, related growth factors in the VEGF family.

The immunology business unit is focused on products for the treatment of immune diseases including rheumatoid arthritis, atopic dermatitis, asthma, and nasal polyposis. The products under development include Sarilumab in rheumatoid arthritis and Dupilumab in atopic dermatitis and asthma, developed in collaboration with Regeneron.

Scope of the Report

-- About the Company - Historical Details, Current Ownership Structure and basic overview of Sanofi Genzyme in terms of revenue, net income, and operating income.

-- Financials - Details about Sanofi Genzyme listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.

-- Products / Services - Listing of the company’s entire portfolio along with description of individual products / services providing a clear picture of their target audience.

-- Company SWOT Analysis - Outlines Sanofi Genzyme’s strengths, weaknesses, and opportunities and threats facing the company.

-- Recent Developments - Showcases Sanofi Genzyme’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.

-- Strategic Evaluation - Provides an overview of Sanofi Genzyme’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.

-- Technology Landscape - Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken buy the company at present along with outlook.

Key Questions Answered

-- What domain does Sanofi Genzyme operate and what are key points about it?

-- What is the product / service portfolio of Sanofi Genzyme?

-- How has Sanofi Genzyme performed financially from the 2013?

-- How does Sanofi Genzyme rank among its peers in terms of revenue and market share?

-- What are Sanofi Genzyme strengths and weaknesses and what opportunities and threats does it face?

-- What are Sanofi Genzyme’s main growth strategies and how successful has the company been at implementing them?

-- What is the in-house technical capability of Sanofi Genzyme? Where does it procure / outsource it?

Reasons to buy

-- Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own

-- Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at very competitive cost

-- 12 hour delivery time fulfilling your urgent requests as per your requirement

-- On-demand customization options that can completely cater to your needs by focusing the report onto given specifics